UBS Maintains Sell on Moelis & Co, Lowers Price Target to $30

UBS analyst Brennan Hawken maintains Moelis & Co (NYSE:MC) with a Sell and lowers the price target from $32 to $30.

byBenzinga Newsdesk

January 9, 2023

1 minute read

UBS analyst Brennan Hawken maintains Moelis & Co (NYSE:MC) with a Sell and lowers the price target from $32 to $30.

Marketwise Q2 Sales $142.10M Up From $82.80M YoY

By Benzinga Newsdesk

Today, 10:33 PM

Marketwise (NASDAQ:MKTW) reported $142.10 million in sales this quarter. This is a 71.62 percent increase over sales of $82.80 million the same period last year.

MKTW

RingCentral Q3 EPS $0.36 Beats $0.33 Estimate, Sales $414.63M Beat $393.42M Estimate

By Benzinga Newsdesk

Today, 10:33 PM

RingCentral (NYSE:RNG) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.33 by 9.09 percent. This is a 38.46 percent increase over earnings of $0.26 per share from the same

RNG

NanoVibronix Shares Gain As PainShield Shows Effectiveness In Treating Soft Tissue Pain

By Vandana Singh

Today, 10:33 PM

NanoVibronix Inc (NASDAQ:NAOV) has announced results from a randomized, double-blind study to evaluate the safety and effectiveness of the NanoVibronix PainShield.…

NAOV

Luminar Technologies Q2 EPS $(0.08) Misses $(0.07) Estimate, Sales $6.30M Miss $6.32M Estimate

By Bill Haddad

Today, 10:33 PM

Luminar Technologies (NASDAQ:LAZR) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. The company reported quarterly sales of $6.30 million which

LAZR

UBS Maintains Sell on Moelis & Co, Lowers Price Target to $30

Related Posts

Marketwise Q2 Sales $142.10M Up From $82.80M YoY

RingCentral Q3 EPS $0.36 Beats $0.33 Estimate, Sales $414.63M Beat $393.42M Estimate

NanoVibronix Shares Gain As PainShield Shows Effectiveness In Treating Soft Tissue Pain

Luminar Technologies Q2 EPS $(0.08) Misses $(0.07) Estimate, Sales $6.30M Miss $6.32M Estimate